BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16314628)

  • 1. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
    Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
    J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
    Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
    Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.
    Saif MW; Black G; Johnson M; Russo S; Diasio R
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):771-5. PubMed ID: 16552574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
    Saif MW; Hashmi S; Bell D; Diasio RB
    Expert Opin Drug Saf; 2009 Sep; 8(5):507-14. PubMed ID: 19663627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
    Boskos CS; Liacos C; Korkolis D; Aygerinos K; Lamproglou I; Terpos E; Stoupa E; Baltatzis G; Beroukas K; Papasavvas P; Dimopoulos MA; Bamias A
    J Surg Oncol; 2010 Oct; 102(5):408-12. PubMed ID: 19877119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
    Garcia AA; Blessing JA; Lenz HJ; Darcy KM; Mannel RS; Miller DS; Husseinzadeh N;
    Gynecol Oncol; 2005 Mar; 96(3):810-7. PubMed ID: 15721430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
    Koizumi W; Okayasu I; Hyodo I; Sakamoto J; Kojima H;
    Anticancer Drugs; 2008 Sep; 19(8):819-24. PubMed ID: 18690094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
    Blanquicett C; Saif MW; Buchsbaum DJ; Eloubeidi M; Vickers SM; Chhieng DC; Carpenter MD; Sellers JC; Russo S; Diasio RB; Johnson MR
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8773-81. PubMed ID: 16361565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
    Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
    Hasegawa K; Okamoto H; Kawamura K; Kato R; Kobayashi Y; Sekiya T; Udagawa Y
    Eur J Obstet Gynecol Reprod Biol; 2012 Jul; 163(1):67-70. PubMed ID: 22480411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
    Vallböhmer D; Yang DY; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
    Int J Oncol; 2007 Aug; 31(2):413-8. PubMed ID: 17611699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
    Saito K; Khan K; Yu SZ; Ronson S; Rhee J; Li G; Van Echo D; Suntharalingam M; O'Malley BW; Li D
    Laryngoscope; 2009 Jan; 119(1):82-8. PubMed ID: 19117293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
    Garcia AA; Blessing JA; Darcy KM; Lenz HJ; Zhang W; Hannigan E; Moore DH
    Gynecol Oncol; 2007 Mar; 104(3):572-9. PubMed ID: 17049588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
    Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
    J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
    Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
    Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
    Nishina T; Hyodo I; Miyaike J; Inaba T; Suzuki S; Shiratori Y
    Eur J Cancer; 2004 Jul; 40(10):1566-71. PubMed ID: 15196541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.